Edward M. Kaye, M.D.

Edward M. Kaye, M.D.

DirectoratStoke Therapeutics· In proxies 2022–2025

Pay in FY2025-42% from the year before · Stoke Therapeutics stock +187.8% the same year

Edward M. Kaye, M.D. was paid $3.2M in FY2025 (Dec), down 42%. Stoke Therapeutics stock rose 187.8% that year.

Pay$100 in the stock at the end of FY21 → $132
Pay is from the Summary Compensation Table of each Stoke Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. CytokineticsPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years
  2. Stoke TherapeuticsPublic company · 4 yr
    • Former Chief Executive Officer2022 – Present · 4 yrStock in role +20%
  3. Stoke TherapeuticsPublic company · 11 yr
    • Director2015 – Present · 11 yrNo stock prices for these years
  4. Avidity Biosciences, Inc.Public company
    • Director? – PresentNo stock prices for these years
  5. Convergence BioPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards2

  • CytokineticsDirector · 9 yr on the boardIndependentAudit, Compensation and Talent, Science and Technology—Paid as an executive
  • Stoke TherapeuticsDirector · 8 yr on the boardNot independentResearch and Development—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?